论文部分内容阅读
目的评价TP方案时辰化疗治疗晚期非小细胞肺癌的疗效和安全性。方法紫杉醇135mg/m2+生理盐水250ml,第1天,03:00~05:00静脉输注,其中高峰输注时间03:30~04:30,输注速度150ml/h,其余时间输注速度100ml/h;顺铂80mg/m2+生理盐水500m第2天,15:30~16:30静脉输注,其中高峰输注时间15:30~16:30,输注速度300ml/h,其余时间输注速度为200ml/h;每位患者至少接受2个疗程化疗。结果53例非小细胞肺癌(NSCLC)完全缓解1例,部分缓解16例,稳定25例,进展11例,有效率为32.1%(17/53),临床控制率为79.2%(42/53)。化疗后Karnofsky评分显著提高(P=0.032)。生活质量改善率为41.5%,功能状态改善率为67.9%,临床症状改善率为81.1%。全组无疾病进展时间4.1个月(95%CI,2.9~6.9),中位生存时间7.8个月,一年生存率为38.3%(18/47)。骨髓抑制是主要的毒副作用,第1个疗程后粒细胞降低发生率37.2%(20/54),但在第2个疗程加用粒细胞集(G-CSF)后降至12.1%(11/91),3或4度粒细胞减少分别发生在9.3%(5/54)和2.2%(2/91)的患者中。腹泻和神经病变通常是轻度的,经对症处理可缓解。结论TP方案时辰化疗治疗晚期非小细胞肺癌疗效确切,可以改善生活质量,不良反应可以耐受,安全性高,可在临床上推广。
Objective To evaluate the efficacy and safety of TP regimen chemotherapy in the treatment of advanced non-small cell lung cancer. Methods Paclitaxel 135mg / m2 + saline 250ml, the first day, 03:00 ~ 05:00 intravenous infusion, peak infusion time 03:30 to 04:30, infusion speed 150ml / h, the rest of the infusion rate 100ml / h; cisplatin 80mg / m2 + saline 500m on the second day, 15:30 ~ 16:30 intravenous infusion, peak infusion time 15:30 ~ 16:30, infusion speed 300ml / h, the rest of the infusion Speed of 200ml / h; each patient received at least two courses of chemotherapy. Results In 53 NSCLC patients, 1 patient was completely relieved, 16 patients were partially relieved, 25 patients were stable and 11 patients were advanced. The effective rate was 32.1% (17/53) and the clinical control rate was 79.2% (42/53) . Karnofsky scores increased significantly after chemotherapy (P = 0.032). The quality of life improvement rate was 41.5%, functional status improvement rate was 67.9%, clinical symptoms improvement rate was 81.1%. The overall progression-free time was 4.1 months (95% CI, 2.9-6.9). The median survival time was 7.8 months and the one-year survival rate was 38.3% (18/47). Myelosuppression was the major toxic side effect. After the first course of treatment, the incidence of neutropenia was 37.2% (20/54), but decreased to 12.1% after the second course of treatment with G-CSF (11 / 91) and grade 3 or 4 neutropenia occurred in 9.3% (5/54) and 2.2% (2/91) of patients, respectively. Diarrhea and neuropathy are usually mild, symptomatic treatment can be alleviated. Conclusion TP regimen chemotherapy for the treatment of advanced non-small cell lung cancer is effective, can improve the quality of life, adverse reactions can be tolerated, high safety, and can be clinically promoted.